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Abstract
Purpose of Review Stress has long been suspected to be interrelated to (abdominal) obesity. However, interindividual differences
in this complex relationship exist. We suggest that the extent of glucocorticoid action partly explains these interindividual
differences. We provide latest insights with respect to multiple types of stressors.
Recent Findings Increased long-term cortisol levels, as measured in scalp hair, are strongly related to abdominal obesity and to
specific mental disorders. However, not all obese patients have elevated cortisol levels. Possibly, the interindividual variation in
glucocorticoid sensitivity, which is partly genetically determined, may lead to higher vulnerability to mental or physical stressors.
Other evidence for the important role for increased glucocorticoid action is provided by recent studies investigating associations
between body composition and local and systemic corticosteroids.
Summary Stress may play a major role in the development and maintenance of obesity in individuals who have an increased
glucocorticoid exposure or sensitivity. These insights may lead to more effective and individualized obesity treatment strategies.
Keywords Obesity . Stress . Cortisol . Hair cortisol . Glucocorticoid receptor . Glucocorticoid receptor polymorphisms .
Corticosteroids
Introduction
Obesity is a rapidly increasing pandemic with major conse-
quences for public health. In the past years, evidence is mount-
ing that stress, and particularly, an increase of the glucocorti-
coid stress hormone cortisol plays a role in the development of
obesity. However, it seems that not all individuals respond to
stress in the same way. This poses the question whether there
is interindividual variation in the biological response to stress.
In this review, we will explain how individual susceptibility to
stress and obesity is determined, with a focus on cortisol, one
of the main hormones involved in the biological stress re-
sponse. Cortisol, a glucocorticoid (GC) hormone, is known
to cause a redistribution of white adipose tissue to the abdom-
inal region and in addition increases appetite with a preference
for energy-dense food (“comfort food”) [1•]. Patients who are
chronically exposed to high levels of glucocorticoids, like in
Cushing’s syndrome or when using high doses of exogenous
GC, develop abdominal obesity, metabolic syndrome (MetS),
and eventually cardiovascular diseases (CVD).
Interestingly, in our modern society, the obesity pandemic
coincides with an increase in factors that enhance cortisol
production, such as chronic stress, consumption of food with
a high glycemic index, and a reduced amount of sleep [2, 3].
This suggests a vicious circle, where increased glucocorticoid
action, obesity, and stress interact and amplify each other [4].
This hypothesis is supported by recent studies demonstrating
significant correlations between obesity and long-term cortisol
levels, as measured in scalp hair, in both adults [5, 6••, 7] and
children [8]. This article will briefly discuss this novel tech-
nique of cortisol measurement and its implications in stress-
related research in the past decade and in the future [9].
Additionally, it will focus on the mechanisms and conditions
that influence the sensitivity to GC at a molecular level.
This review will also provide a short overview of recent
developments regarding several types of stress (e.g., acute/
chronic stress, mental/physical stress but also exposure to
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exogenous stress hormones) and their relationships with obe-
sity. In addition, existing literature explaining interindividual
differences in these complex relationships will be discussed.
All these concepts are then integrated in a conceptual model
with obesity, chronic stress, and increased glucocorticoid ac-
tion as its key components.
Stress
Stress, both physical and psychological, can be seen as a part
of life that every individual will experience to some extent.
Goldstein described stress as a condition in which expecta-
tions, whether genetically programmed, established by prior
learning, or deduced from circumstances, do not match current
or anticipated perceptions of the internal or external environ-
ment [10]. This mismatch between what is observed or sensed
and what is expected or programmed evokes patterned, com-
pensatory responses. This assembly of responses is generally
called the “stress response” and applies to mental stress. From
a biological perspective, there are also other types of stressors,
such as sleep deprivation, pain, inflammation, or use of exog-
enous glucocorticoids (GCs), which can all elicit a stress re-
sponse at the cellular level.
The Acute Stress Response
Within seconds after a (perceived) stressor, catecholamines
such as epinephrine and norepinephrine (associated with the
fight/flight response) are produced in the sympathetic nervous
system and in the adrenal medulla. They increase heart rate
and stroke volume and cause vasoconstriction of blood vessels
in the skin and the gut. Furthermore, epinephrine stimulates
glycogenolysis in the liver, leading to higher serum glucose
levels providing energy for a defensive reaction [11].
Peripherally produced epinephrine and norepinephrine do
not cross the blood-brain barrier. Within the brain, the locus
coeruleus produces norepinephrine and supports arousal, vig-
ilance, and narrowing of attention [12••].
Catecholamines are also linked to the hypothalamic-
pituitary-adrenal (HPA) axis with its end-product cortisol,
which responds within minutes to hours and supports the ac-
tion of catecholamines. Following an acute stressor, the re-
lease of corticotropin-releasing-hormone (CRH) is initiated
from neurons in the parvocellular division of the
paraventricular nucleus (PVN) [12••, 13]. This leads to a rise
in adrenocorticotropic hormone (ACTH), which is secreted in
a pulsatile way after initiation by CRH [12••]. The CRH re-
lease depends on the stressor’s duration, intensity, and feed-
back. ACTH subsequently stimulates the production of GCs
from cholesterol and other steroid precursor hormones in the
adrenal glands.
CRH suppresses appetite acutely after stress [14], probably
by inhibiting food intake that is stimulated by neuropeptide Y
(NPY) [15]. However, once extra GCs are produced, the in-
take of food is stimulated [15, 16], which occurs already as
soon as 1 h after injection of CRH [17]. GCs stimulate the
actions of NPYand reduce the sensitivity of the brain to leptin
and to insulin by enhancing insulin resistance. The latter also
inhibits feeding-stimulatory pathways in the brain [15].
Moreover, GC specifically increase a preference for food that
is rich in fat and sucrose [1•, 15]. An acute stress response
ends when the stressor disappears. At this point, CRH release
from the PVN is inhibited by several mechanisms that are
mainly driven by cortisol, thereby reducing its own production
[12••]. The glucocorticoid receptor (GR) is crucial for this
negative feedback loop [12••]. The rapid termination of
CRH secretion and subsequent decrease in ACTH release
causes GC secretory activity to gradually return to baseline
[12••], thereby ending the stress response.
The increased secretion and effects of these major stress
mediators that are induced by acute stress, though essential
for the survival of an organism, can also have negative effects.
Excessive sympathetic activity may lead to hypertensive situ-
ations whereas increased parasympathetic action may lead to
hypotensive situations. In this way, angiokinetic phenomena
such as migraine may develop [18]. Furthermore, the CRH
that is involved in acute stress can induce degranulation of
mast cells in specific organs, thereby eliciting asthma or ecze-
ma. Also, acute stress can lead to different types of pain,
gastrointestinal symptoms, and mental disturbances such as
panic attacks and psychoses [18].
Chronic Stress
The main effectors in chronic stress are GC, such as cortisol.
The effects of GC are, at a cellular level, exerted through two
intracellular receptors, the mineralocorticoid receptor (MR)
and the glucocorticoid receptor (GR). Although the MR has
a stronger affinity for GCs, the presence of 11-beta-
hydroxysteroid dehydrogenase type II (11βHSD2), which lo-
cally converts cortisol to inactive metabolites, prevents a glu-
cocorticoid action in various tissues, such as the kidneys and
certain brain areas [19].
When GC bind to the GR, this receptor will translocate into
the nucleus, where it influences gene expression [20]. GRs are
widely distributed throughout the brain and peripheral tissues;
thus, glucocorticoids are involved in a variety of processes.
They regulate cardiovascular tone; serve as an intermediary in
metabolism through catabolic actions that take place in the
liver, muscle, and adipose tissue; and they impact the inflam-
matory and immune response [21]. In addition, GCs influence
essential functions such as reproduction, growth, behavior,
water and electrolyte balance, and cell proliferation and sur-
vival [13].
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The biological effects of increased levels of endogenous cor-
tisol have a substantial overlap with the effects of chronic expo-
sure to exogenous synthetic glucocorticoids, as they exert their
biological actions through the same receptor [22••]. However,
synthetic glucocorticoids are not bound to cortisol binding glob-
ulin in the plasma and are not metabolized by 11βHSD2 [22••].
Consequences of Chronic Stress
Mental Factors Related to Chronic Stress and HPA
Hyperactivity
It is known that chronic stress is linked to several behavioral
and neuropsychiatric conditions. Regarding the exact patho-
physiological mechanisms, not only speculations have been
made about the effect of CRH [23], but also its end product
cortisol has been hypothesized to have a pathophysiological
role in stress-related mental disorders such as anxiety and
depression [24, 25]. Currently, the relatively novel technique
of hair cortisol concentration (HCC) measurement [26] has
also been implemented in research of mental disorders and
conditions that are related to stress [27]. This unique and re-
cently developed and optimized technique measures long-
term cortisol levels using scalp hair [9, 26] and thus over-
comes the limitations of serum, saliva of urine cortisol analy-
sis that represents “snapshots” of cortisol levels instead of a
consistent measurement of chronic cortisol levels. Studying
the correlation between mental states and traits and chronic
cortisol levels is important, as this may be an important deter-
minant in the vicious circle of stress and obesity [28•].
Recently, Stalder et al. reported in a meta-analysis that per-
ceived chronic stress is associated with an estimated 22%
elevated HCC. Particularly, groups who had stress ongoing
at the time of study exhibited a 43% increase of HCC [6••].
Also, hypercortisolism was found in scalp hair in patients
reporting severe symptoms of burnout [29]. Interestingly,
Jackson et al. recently found that obese individuals who ex-
perience discrimination that is explicitly weight-related exhib-
it higher HCC levels than obese persons who did not feel
discriminated because of their weight. This effect was not
present for discrimination in general [30]. In this way, weight
discrimination by itself may contribute to progression of the
obese state by increasing cortisol levels.
Furthermore, Karlen et al. found that children with more
psychosocial exposures during pregnancy and early life had
higher HCC levels [31]. It was also found that a lower family
income [32] and lifetime exposure to trauma [33] were asso-
ciated with a higher HCC. In adults, however, a past trauma
corresponded with lower HCC [6••, 34–36], whereas in the
acute phase, cortisol levels were raised [37]. For example, a
recent study shows that permanently staying asylum seekers
have lower HCC than the reference group whereas recently
fled asylum seekers have higher HCC, but no differences were
found between the recently fled asylum seekers with post-
traumatic stress disorder (PTSD) and those without PTSD
[38]. Possibly, a traumatic experience temporarily raises sys-
temic cortisol levels, which fade over the course of time lead-
ing to subsequent lower HCC.
Regarding other mental disorders, it has been challenging to
prove a consistent relation between HCC and mood disorders
such as depression and bipolar disorder [6••, 29]. For the diag-
nosis of depression, some studies reported higher HCC com-
pared to controls [39, 40], whereas others found no association
[41, 42] or lower HCC [43, 44]. Regarding depressive symp-
toms, strong correlations with cortisol have been described [45,
46], whereas others found no association [47, 48]. The use of
diverse populations with relatively small sample sizes may be
accountable for these differences, as well as the duration of
symptoms. However, large study comprising 921 participants
with a current or remitted depressive and/or anxiety disorder
confirmed a significant association with the presence of a co-
morbid depressive and anxiety disorder. In this study, the sever-
ity of depressive symptoms and anxiety symptoms was also
correlated to HCC (Sabine M. Staufenbiel, Brenda W.J.H
Penninx, Lotte Gerritsen, Albert M. van Hemert, Gerard
Noppe, Yolanda B. de Rijke, Elisabeth F.C. van Rossum, un-
published results 2018). The use of antidepressants may com-
plicate this research, as they could influence the HPA axis,
possibly by modulating the GR [49]. Specifically, selective se-
rotonin reuptake inhibitors (SSRIs) are associated with higher
HCC in most studies ([50–52]. As depression and obesity are
strongly related in a bidirectional manner, unraveling the shared
pathophysiological mechanisms is of profound interest for fu-
ture combined treatment strategies [28•].
Physical Consequences of Chronic Stress
Chronic stress causes an elevated baseline HPA-activity and
increased HPA axis responsiveness [12••, 53]. In this case, the
prolonged effects of the effector molecules of the stress sys-
tem, including cortisol, norepinephrine, and CRH, can lead to
disorders in the aforementioned target tissues, including a
broad spectrum of inflammatory, metabolic and neuropsychi-
atric diseases [13]. As for the immune system, stress has com-
plex actions. GCs alter the function of leukocytes and other
immune cells, and decrease proinflammatory cytokines. Also,
GCs as well as catecholamines induce a switch from Th1 to
Th2 cells, which increases the risk for auto-immune disorders
such as systemic lupus erythematosus, Graves’ disease, and
allergic conditions [13]. On the contrary, pro-inflammatory
cytokines have a stimulatory effect on the stress system, which
leads to increased GC levels that again suppress the inflam-
mation [18]. Endocrine consequences following the increased
effect of GCs include inhibition of the growth hormone axis,
thyroid axis, and gonadal axis, contributing to the loss of
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muscle mass and bone mass and visceral fat accumulation that
is seen in increased GC exposure [13]. The subsequent viscer-
al obesity and loss of muscle mass are associated with clinical
parameters comprising the MetS: dyslipidemia and hyperten-
sion and type 2 diabetes mellitus, which can ultimately lead to
cardiovascular diseases [1•].
As mentioned previously, exogenous synthetic GCs exert
roughly the same biological effects as glucocorticoids from
the endogenous pathway [22••]. It is therefore not surprising
that in clinical practice, associations between the use of syn-
thetic corticosteroids and obesity and the metabolic syndrome
are found. Interestingly, obese patients visiting an outpatient
clinic for obesity had used corticosteroids in the last 3 months
nearly twice as often as non-obese controls [54]. We also
observed in a large sample of more than 140,000 adult indi-
viduals from the general population that use of both systemic
and the local types was associated with the presence of meta-
bolic syndrome, as well as an higher BMI. However, causality
still has to be proven. Suggestive of a causal relation is the
meta-analysis of Broersen et al., showing that local corti-
costeroids have systemic effects such as adrenal suppres-
sion [55, 56]. The effects of chronically elevated cortico-
steroid levels have been shown to be modified by genetic
variation in the GR gene [22••]. Individuals carrying GR
gene polymorphisms which are associated with a relative
hypersensitivity seem to be more vulnerable for the adverse
effects such as higher fat percentages, higher serum leptin,
and an adverse cardiometabolic risk profile [57]. This will
be further discussed below.
If future research will show that the relation between obe-
sity and corticosteroid use is causal, it may have large conse-
quences for public health, as a substantial part of the general
population uses these (local) corticosteroids (nearly 11% in
the approximately 140,000 participants of the population-
based Lifelines cohort study) [58]. Furthermore, if we consid-
er the individual differences in the biological effects of these
agents, it seems that specific persons can experience a consid-
erable weight gain after initiation of these agents.
Novel Insights in the Relation Glucocorticoid
Exposure and Obesity
Cushing’s Syndrome as a Model of a Pathological
Status of Stress and Obesity
In the past years, an imbalance between energy intake and
energy expenditure was regarded the main cause of the obesity
pandemic. However, considering the abovementioned effects
of chronic cortisol exposure, evidence is mounting that corti-
sol is also a kingpin in this pandemic. The effects of long-term
exposure to extremely elevated levels of cortisol are demon-
strated by Cushing’s syndrome (CS). This is a condition
characterized by pathologically elevated cortisol levels, usu-
ally caused by a pituitary or adrenal adenoma. In CS, the
excess of cortisol can lead to a variety of clinical manifesta-
tions, such as abdominal obesity, hypertension, abnormal glu-
cose tolerance, and proximal muscle weakness [59]. The strik-
ing resemblance of CS patients and the more common MetS
suggests a causal role for GCs. Importantly, treatment can to
some extent reverse the adverse metabolic and anthropometric
characteristics, although some may remain [60]. This, at least
partial, reversibility of the CS indicates that this presumed
hypercortisolism could provide promising future treatment
opportunities for the metabolic syndrome.
However, when studying the relation between GC and hu-
man obesity, conflicting results were found with respect to
cortisol levels in obesity [61–64]. The diagnostic tests that
were previously used, for measuring cortisol in serum, saliva
or urine, are difficult to interpret when applied to measure
subtle hypercortisolism in “common” obesity. This is mainly
due to the circadian rhythm of cortisol, its pulsatile secretion,
and relatively short half-life in plasma (approximately 66min)
[65], as well as daily variations due to changing circumstances
like acute stress. As previously mentioned, scalp hair analysis
of cortisol overcomes these limitations.
Correlations Between Long-Term Cortisol and Obesity
It has been demonstrated that, on average, obese individuals
have higher hair cortisol levels [7] The meta-analysis of
Stalder et al. also found consistent evidence for a relationship
between HCC and BMI (9.8% increase of hair cortisol for
each 2.5-point increase in BMI) [6••]. Afterwards, several
cohort studies have confirmed the relationship between adi-
posity measures and HCC in adults [5, 66]. Interestingly, also
in a large cohort study of more than 3000 6-year-old children,
those with the highest hair cortisol concentrations had an al-
most 10-fold increased risk of obesity [8]. In the latter study,
cortisol was specifically correlated to an increase of abdomi-
nal fat mass, which is similar to the effect of cortisol in CS. In
addition to these cross-sectional findings, HCC also correlated
to a more persistent obesity over time [5]. So, on average,
long-term cortisol levels are elevated in obese individuals,
and seem in particular related to increased abdominal fat mass.
This specific distribution may be explained by the greater
density of GRs in visceral adipose tissue than in other adipose
tissues, causing fat redistribution to the abdominal region [1•,
67]. This could be further enhanced by an increased expres-
sion of 11βHSD1 leading to more active cortisol [68].
Potential Mechanisms and Treatment Targets
of Elevated Cortisol in Obesity
This brings up the question what causes the increased chronic
cortisol levels in the majority of patients with obesity and
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whether there are more susceptible individuals. Despite the
elevated average chronic cortisol levels in obesity, not all in-
dividuals with obesity have higher HCC.When taking a closer
look at the sample of obese individuals, it can be observed
that, within the obese group, roughly half of the obese patients
appear to be normocortisolistic, whereas the others can be
categorized as hypercortisolistic [7]. One can be speculate that
hypercortisolistic obesity may represent more abdominal obe-
sity and is more tightly linked to the metabolic syndrome and
cardiovascular diseases. This concept is supported by studies
showing that persons with the highest hair cortisol had the
highest risk of metabolic syndrome [69] and cardiovascular
diseases [70]. It is conceivable that these “hypercortisolistic”
obese persons could benefit more from cortisol reducing treat-
ment strategies than “normocortisolistic” obese individuals.
Studies to elucidate this issue are ongoing.
There are several mechanisms that can potentially contrib-
ute to higher cortisol levels in individuals with obesity. First of
all, there could be an overactivity of the HPA axis, including
increased CRH and ACTH. This could be due to the intake of
food with a high glycemic index [71], chronic stress [72],
chronic pain [73], alcohol [74], and chronic sleep deprivation
[75]. HPA activity also seems higher in patients with the night
eating syndrome [76], although it is not known whether the
actual timing of meals may influence the HPA axis. Secondly,
inflammatory markers such as interleukin-6, TNF-alpha, and
IL-1β can influence the HPA axis [77]. Thirdly, it is conceiv-
able that the different cortisol levels may be due to individual
variation in enzymes that are involved in cortisol metabolism,
such as 11-β-hydroxysteroid dehydrogenases enzymes type 1
and 2 (11βHSD1 and 11βHSD2). The enzyme 11βHSD1
catalyzes the regeneration of the inactive cortisone to its active
form cortisol. It was found to have a significantly higher ex-
pression in adipose tissue of obese individuals versus fat tissue
of non-obese individuals, both in men and in women in most
studies [64]. In the liver of obese patients, however, the activ-
ity of 11βHSD1 seems to be decreased [64, 78]. Moreover, in
obesity, there may also be other enzymes responsible for al-
tered cortisol levels or altered effects of cortisol, that include
5α and 5β reductases [78] and bile acids [79]. Also, severe
liver steatosis could play a role, as the activity of hepatic
enzymes responsible for cortisol clearance and regeneration
is altered in patients with hepatic steatosis [80].
In the past years, several studies have investigated the po-
tential of 11βHSD1 inhibitors and found modest effects on
glycemic control in patients with type 2 diabetes mellitus,
however not enough to compete with existing medication
[81, 82]. The effect on other features of the metabolic syn-
drome, including hypertension, dyslipidemia, and obesity,
was thus far also modest [82]. It is conceivable that these
agents could be more potent if they are used selectively in
hypercortisolistic patients with obesity. Future studies need
to confirm this hypothesis.
Also, GR antagonists, such as mifepristone, lowered
fasting glucose and insulin levels when given simultaneously
with metyrapone in men with type 2 diabetes [83]. Other po-
tential strategies to target hypercortisolism include non-
pharmacological options such as mindfulness, which has been
studied in patients with structural heart disease [84].
Glucocorticoid Sensitivity at aMolecular Level
and the Relation with Obesity
and Stress-Related Disorders
The Glucocorticoid Receptor
The clinical effects of glucocorticoids are determined not only
by their quantity, but also by the individual sensitivity to glu-
cocorticoids at a tissue level [85]. Cases of extreme glucocor-
ticoid sensitivity, such as primary generalized glucocorticoid
hypersensitivity, and of its opposite, extreme glucocorticoid
resistance (Chrousos syndrome) have been described [86];
however, there are also variations within the normal range.
A key player in glucocorticoid action is the GR, also known
as nuclear receptor subfamily 3, group C, member 1, or
NR3C1. When cortisol binds to the GR, it becomes activated
and moves into the nucleus. In the cytoplasm, a multiprotein
complex, which is formed by several folding chaperone pro-
teins (heat shock proteins and FK506 binding proteins,
FKBPs), regulates the activity of the GR [87]. The GR can
activate or repress transcription of target genes through several
mechanisms, which include direct interaction with the
glucocorticoid-responsive elements in the promoter regions
of target genes, or interaction with other transcription factors
thereby influencing gene expression indirectly [88]. Thus, the
individual sensitivity for endogenous and exogenous gluco-
corticoids can be influenced by many factors and conditions,
including not only altered uptake, altered steroid-binding pro-
teins in the plasma, or alterations in the 11βHSD activity, but
also the GR-expression level, the ligand binding affinity of
GR, the ability of GR to bind DNA, or by competition for
DNA-binding with other inflammatory transcription factors
[88]. Several methods have been used to study glucocorticoid
sensitivity: in vivo by, e.g., very low dose (0.25 mg) dexa-
methasone suppression tests, and in vitro, e.g., by glucocorti-
coid receptor transactivation or transrepression activity using
bioassays or gene expression profiles [89, 90].
Individual Variations in Glucocorticoid Sensitivity
and Their Consequences for Body Composition
and Mental Status
A number of acquired diseases are currently linked to differ-
ences in tissue sensitivity to glucocorticoids, such as HIV
(which is associated with glucocorticoid hypersensitivity)
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[91, 92] and inflammatory states such as rheumatoid arthritis,
osteoarthritis, inflammatory bowel disease, and asthma (asso-
ciated with resistance to glucocorticoids) [91].
However, also certain polymorphisms in the GR gene
(NR3C1) have been identified that influence glucocorticoid sen-
sitivity, of which a small number have been studied most inten-
sively: Tth111I, ER22/23EK, N363S, BclI, and GR-9β [93].
The BclI polymorphism, associated with an increase in
glucocorticoid sensitivity, was linked to increased central obe-
sity and BMI, as well as other parameters that are related to the
metabolic syndrome, including insulin resistance and in-
creased blood pressure [94, 95]. Roerink et al. recently found
that the BclI polymorphism is associated with an adverse car-
diometabolic risk profile in patients in long-term remission of
Cushing syndrome [57]. The exact mechanism that may cause
the BclI polymorphism to increase glucocorticoid sensitivity
has not been unraveled.
The N363S polymorphism is also related to an increase in
glucocorticoid sensitivity and has been associated with a
higher BMI and increased LDL cholesterol in elderly [96].
However, the positive relationship of N363S and BMI has
not consistently be observed [97, 98••]. This polymorphism
has been shown to lead an increased transactivational capacity
of the GR in vitro [99] and to altered gene expression [90].
As an opposite to N363S and BclI, the combined
ER22/23EK polymorphism has been shown to lead to a mild
glucocorticoid resistance, both in vivo as in vitro studies [99,
100]. In line with a long-term decreased GC action, we previ-
ously observed sex-specific changes in body composition.
Male carriers of this polymorphism have more muscle mass,
increased muscle strength, and are taller; female carriers have
a smaller waist circumference [101]. Furthermore, it has been
associated with higher insulin sensitivity and lower fasting
insulin, CRP, and LDL-cholesterol levels [98••].
The GR-9β polymorphism has no effect on GR
transactivation but seems to decrease transrepression activity of
the GR. This type of mild GC resistance may reduce the immu-
nosuppressive actions of glucocorticoids and has been associat-
ed with an increased incidence of coronary heart disease [93].
The abovementioned polymorphisms can be integrated in
five different haplotypes of the GR-gene [93]. Recently, these
haplotypes were studied in 12,552 individuals of the Lifelines
cohort study [102]. Haplotype 4, containing the N363S poly-
morphism, showed an increase in MetS in young adult males.
Interestingly, this haplotype increased the odds for MetS spe-
cifically in patients with a low education status. It is conceiv-
able that in the context of stressful circumstances, such as
poverty or unemployment, the effects of the stress hormone
cortisol may cause extra harm in individuals carrying the
N363S variant. Thus, genetic variations in the GR-gene may
influence the metabolic phenotype, which seems also influ-
enced by environmental factors, and may contribute to indi-
vidual vulnerability for the biological effects of stress.
Genetic variations in the HPA axis could play a role in
stress-related mental disorders, such as post-traumatic stress
disorder [103] and mood disorders [104]. Previous studies
have also specifically focused on the link between GR poly-
morphisms and depression. As to the variants associated with
increased glucocorticoid sensitivity, most studies have fo-
cused on the BclI polymorphism and found that depressive
patients were more likely to be BclI variant carriers
[105–107]. On the other hand, the relative glucocorticoid-
resistant ER22/23EK SNP was also more frequently observed
in patients with a major depressive disorder [105, 108], which
concurs with the common observation of relative glucocorti-
coid resistance (with biochemical assessments) in depressive
patients. One other specific example is FKBP5, a cochaperone
in the heat shock protein 90-steroid receptor complex, which
not only is induced by GR activation, but also inhibits the GR,
thus creating an ultra-short intracellular negative feedback
loop [87]. High FKBP5 levels are known to decrease GR
signaling by alteration of the GR complex. Several common
genetic variants within this GR signaling pathway have been
linked to depression [109]. These studies show that either
increased or decreased exposure to GCs at the molecular level,
as determined by an individual genetic makeup, seems to be
involved in major depressive disorder.
The Interplay Between the Stress System
and Obesity
Integrating the abovementioned aspects, a conceptual model for
the interplay between the stress system and obesity in which
individual patient characteristics play a central role has been
proposed (Fig. 1). The end effects of stress with respect to
weight gain can be accomplished in different ways due to the
various properties of glucocorticoids. High levels of cortisol
can, for example, increase appetite with a preference for “com-
fort food” and cause white adipose tissue to redistribute to the
abdominal region [1•], which may ultimately lead to abdominal
obesity [4]. Interestingly, it had been observed that glucocorti-
coids may decrease the sensitivity to adrenergic stimulation of
brown fat [110, 111]. Furthermore, exogenous glucocorticoid
administration increases the intrahepatic conversion of corti-
sone to cortisol thereby potentially contributing to the vicious
circle [112]. This relationship between (chronic) stress and obe-
sity mediated by increased glucocorticoid action may in some
persons be greater by exposure to factors enhancing the stress
response. Biological factors, such as carrying glucocorticoid
sensitive GR gene variants, or a disrupted diurnal cortisol
rhythm by decreased sleep and/or shift work, can potentially
lead to higher glucocorticoid effects and thus make certain per-
sons more prone to weight gain, and obesity. Moreover, the
same holds for other environmental and behavioral factors,
such as intake of food with high glycemic index, excessive
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alcohol use, and chronic pain, all possibly leading to increased
cortisol levels and higher body weight. [71, 113].
On the other hand, obesity per se can also lead to increased
chronic stress to varying degrees depending on certain indi-
vidual characteristics. Persons experiencing, for example,
weight stigma are known not only to experience more stress
[114] but also to have higher long-term cortisol levels [30].
Additionally, persons with obesity are more likely to suffer
from mental (e.g., depression) and physical disorders (e.g.,
OSAS, chronic pain due to weight load) which can in turn
lead to chronic stress and/or higher cortisol levels. This can
even be exaggerated by the use of certain medications indicat-
ed for obesity-related comorbidities, such as corticosteroids
for arthrosis or asthma.
Fig. 1 Conceptual model of the interplay between the stress system and
obesity. Various individual characteristics are proposed to play a role in
initiating a vicious circle of increased activation of the stress system (both
by perceived chronic stress as well as increased net glucocorticoid effect
by either endogenous or exogenous GCs) and obesity in a bidirectional
manner. Abbreviations: GC, glucocorticoid; SNP, single nucleotide
polymorphism; OSA, obstructive sleep apnea
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Thus, in this and many other ways, a vicious circle may be
formed that maintains chronic stress, obesity, and increased
GC action, leading to even more weight gain and/or impeding
weight loss.
Conclusions
Summarizing recent literature, it can be concluded that there
are more susceptible individuals in the bidirectional relation
between stress and obesity. This can be partly traced back to a
third key player affecting stress and obesity: increased gluco-
corticoid action. The latter is influenced by individual GC
sensitivity and altered levels of GCs, which have both been
associated with body composition and mental disorders in
recent studies.
Future studies may yield more insight into the vicious cir-
cle of obesity, stress, and increased GC action, whichmay lead
to more, individualized treatment strategies that integrate obe-
sity and stress.
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